A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Plerixafor (Primary) ; Busulfan; Busulfan; Cyclophosphamide; Etoposide; Fludarabine; Fludarabine; Melphalan
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Stem cell mobilisation
- Focus Therapeutic Use
- 13 Jun 2017 Status changed from active, no longer recruiting to completed.
- 20 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
- 20 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Apr 2017.